BeNeLuxBelgiumNetherlandsLuxembourg

ActoGeniX: 20 million euros round

16.03.2007

Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.

BeNeLuxBelgiumNetherlandsLuxembourg

13.01.2011

Brussels – For the first time, researchers from Vrije Universiteit Brussels, VIB and Stanford University have frozen adrenaline binding to its hyperdynamic receptor for structural analysis (Nature,doi:10.1038/nature09648). The...

BeNeLuxBelgiumNetherlandsLuxembourg

12.01.2011

Hilden/Berlin – Qiagen NV has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a pioneer in the field of deep sequencing based therapy guidance, clinical trial stratification, and ...

BeNeLuxBelgiumNetherlandsLuxembourg

04.11.2010

Mechelen – Genomics and drug discovery services company Galapagos NV, has triggered another milestone payment in its alliance with Janssen Pharmaceutica NV in the field of rheumatoid arthritis, receiving a milestone payment of...

BeNeLuxBelgiumNetherlandsLuxembourg

04.11.2010

Mechelen – Belgian service and drug development specialist Galapagos NV has raised EUR28.7m through the sale of 2.4 million shares at a 12 per share in a private placement. The share price represents an 8 % discount to Galapagos’...

BeNeLuxBelgiumNetherlandsLuxembourg

04.11.2010

Brussels – The animal welfare group “Four Paws” has called on the European Commission to stop considering postponement of the ban to end animal testing for cosmetics. According to Directive 76/768/EEC animal tests for...

BeNeLuxBelgiumNetherlandsLuxembourg

04.11.2010

Brussels – New draft legislation from the European Commission proposes a ban in the bloc on marketing foods from cloned animals for the next five years. Health Commissioner John Dalli said that the new rules are not based on food...

BeNeLuxBelgiumNetherlandsLuxembourg

03.11.2010

Brussels – Biopharma giant UCB Group has secured exclusive rights to two drug candidates for treating Parkinson’s disease from Swiss drug developer Synosia Therapeutics AG. Synosia will receive an undisclosed upfront payment and...

Displaying results 61 to 70 out of 304

< Previous 61-70 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/6/article/actogenix-20-million-euros-round.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • 4SC0.97 EUR15.48%
  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%

FLOP

  • MOLOGEN6.60 EUR-13.16%
  • WILEX2.15 EUR-1.83%
  • ADDEX3.40 CHF-1.16%

TOP

  • BIOFRONTERA2.92 EUR32.7%
  • BB BIOTECH157.00 EUR7.2%
  • ADDEX3.40 CHF6.6%

FLOP

  • PAION2.22 EUR-31.9%
  • CYTOS0.17 CHF-19.0%
  • MAGFORCE5.95 EUR-15.6%

TOP

  • SANTHERA84.30 CHF2248.2%
  • CO.DON2.84 EUR202.1%
  • PAION2.22 EUR161.2%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 22.10.2014


Current issue

All issues

Product of the week

Products